Purchase Order 75F40121P00541

Award Date 8/31/21
Potential Completion Date 8/31/26
Potential Value $376K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a firm-fixed-price purchase order to Simulations Plus Inc., a for-profit software company specializing in pharmaceutical modeling and simulation. The contract, valued at $109,798.77, is for the purchase of 50 GastroPlus licenses, 30 IVIVCPlus module licenses, and 30 PBPK Plus licenses. The contract has no set-aside designation and is not associated with a larger contract vehicle. Simulations Plus has previously provided similar software...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Simulations Plus Inc., a prime contractor that specializes in drug discovery and development simulation and modeling software. The $130,000 contract is for the extension and validation of Simulations Plus' GastroPlus ocular compartmental absorption and transit model. There is no set-aside designation for this contract. Simulations Plus has received over $5 million in...
This is a firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Simulations Plus Inc. for the renewal of ADMET Predictor software licenses and associated support services. The contract, valued at $100,337.38, has an ultimate completion date of February 19, 2026. The original solicitation sought to renew the FDA's existing licenses for the ADMET Predictor software, which is used by the Center for Tobacco Products (CTP) for toxicology data mining and assessing the...
This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Certara UK LIMITED, doing business as Certara, a for-profit limited liability company. The $815,948.00 contract is for Certara's SIMCYP software licenses, which provide physiologically-based pharmacokinetic (PBPK) modeling capabilities to facilitate regulatory decision-making and optimize drug development. The SIMCYP software is used by the FDA's Office of...
The U.S. Food and Drug Administration (FDA) awarded a firm fixed price purchase order to Certara UK Limited, doing business as Certara, a for-profit limited liability company, for SIMCYP software licenses and maintenance support. The $114,316.00 contract will allow the FDA's Office of Clinical Pharmacology Drug Reviewers to complete their review of investigational new drugs. Certara has previously provided this physiologically-based pharmacokinetic modeling software to the FDA and...
This is a $845,852.26 firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Certara USA Inc., a leading provider of biosimulation software and consulting services for the pharmaceutical industry. The contract is for the renewal of Certara's Phoenix Quantum software licenses and IVIVC Toolkits, which are essential for the FDA's Office of Clinical Pharmacology to analyze clinical pharmacology and pharmacometric data submitted by drug sponsors. The contract...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Certara USA Inc., a leading provider of biosimulation software and consulting services. The contract, valued at $16,441.10, is for the procurement of software licenses for Certara's proprietary modeling and simulation tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers to conduct...
This is a $11,682 firm-fixed-price purchase order contract awarded by the National Institute on Drug Abuse, a civilian agency within the U.S. Department of Health and Human Services, to Certara USA Inc. The contract is for the licensing and subscription of Certara's proprietary biosimulation and data exploration software tools, including Phoenix WinNonlin, Certara Phoenix, CHEMOFFICE, and SEND EXPLORER. These software products enable federal scientists and reviewers at the National Institutes of...
The Food and Drug Administration (FDA) awarded a $107,856.04 firm-fixed-price purchase order to Anylogic North America, LLC for AnyLogic simulation modeling software licenses and maintenance services. The sole source award does not have a set-aside designation. The award supports the FDA's Center for Devices and Radiological Health (CDRH) in simulating business processes and assessing resource requirements. AnyLogic provides discrete event, agent-based, and system dynamics modeling...
This federal contract awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Certara USA Inc., doing business as Tripos (DE), is for $83,806.57 to provide Certara Phoenix software licenses for pharmacokinetic modeling and simulation. The contract is a firm fixed-price purchase order with a completion date of August 31, 2026. Certara is a technology-enabled drug development and drug safety consultancy that has received numerous prior federal contract...

This firm-fixed-price purchase order awards Simulations Plus Inc., doing business as Simulations Plus, a contract valued at $375,965.05 to provide software licenses for GastroPlus, DDDPlus, and MembranePlus to the Food and Drug Administration (FDA). These software products are used for physiologically-based pharmacokinetic (PBPK) modeling, predicting drug absorption and pharmacokinetics, and conducting virtual bioequivalence studies to support pharmaceutical research, development, and regulatory assessment. The contract has no set-aside designation and runs through August 31, 2026. Simulations Plus has previously received federal grants from the FDA and the National Center for Advancing Translational Sciences to advance its modeling and simulation capabilities in support of drug development and regulatory science initiatives.

Generated 8/20/24, 9:44 AM